Last reviewed · How we verify
NCT04342442
Identification of Novel Targetable Kinases in SR-a GvHD
trial in Graft Versus Host Disease in 24 participants. Completed in 31 December 2019.
31 December 2019
Quick facts
| Lead sponsor | University of Freiburg |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 24 |
| Start date | 1 January 2017 |
| Primary completion | 31 December 2019 |
| Estimated completion | 31 December 2019 |
Conditions studied
- Graft Versus Host Disease — all drugs for Graft Versus Host Disease →
Sponsor
University of Freiburg
Who can join
18 and older, any sex, with Graft Versus Host Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this study, the investigators aim to identify novel targetable kinases in SR-a GvHD patient samples and investigate their role in different immune cell subtypes.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
ROCK1/2 signaling contributes to corticosteroid-refractory acute graft-versus-host disease.
Maas-Bauer K, Stell AV, Yan KL, de Vega E, et al · · 2024 · cited 11× · PMID 38199985 · DOI 10.1038/s41467-024-44703-7
Verify or expand the search:
- PubMed search for NCT04342442
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Graft Versus Host Disease
Currently open trials in the same condition.
- NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
- NCT07006506 — A Study of Belumosudil in People at Risk of Developing Graft-Versus-Host Disease After a Stem Cell Transplant · Phase 2 · recruiting
- NCT06815003 — Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Di · Phase 2 · recruiting
- NCT06705062 — Study Comparing Reduced Versus Standard Dose Post-transplantation Cyclophosphamide in Combination With Post-engraftment · Phase 3 · recruiting
- NCT06252870 — Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-trans · Phase 2 · recruiting
Other University of Freiburg trials
Trials by the same sponsor.
- NCT07517731 — Using Digital Technology for the Prevention of Aedes-Borne Diseases in Colombian Communities · NA · completed
- NCT07053631 — Investigation of a New Window Into Intracranial Pressure: Venous Occlusion Pressure of the Isolated Periorbital Vein · NA · recruiting
- NCT06301412 — Combination of Hypothermia and Thrombectomy in Acute Stroke · Phase 3 · recruiting
- NCT06074874 — Intestinal Biomarker Analysis After ECP for ICI Colitis · completed
- NCT05414552 — ECP for Immune-related Adverse Events After Checkpoint Inhibitor Treatment · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04342442 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Freiburg
- Last refreshed: 13 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04342442.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing